Skip to main content

Table 4 Clinical endpoints

From: Clinical value of drug-coated balloon versus second-generation drug-eluting stent for de novo lesions in large coronary arteries: insights from the real world

 

Before propensity matching

 

After propensity matching

DCB

sDES

P-value

 

sDES

P-value

Number of patients

708

2149

  

704

 

MACE, n (%)

54(7.6%)

140(6.5%)

0.308

 

40(5.7%)

0.143

 CD-TLR, n (%)

39(5.5%)

101(4.7%)

0.387

 

22(3.1%)

0.028

 MI, n (%)

11(1.6%)

32(1.5%)

0.903

 

12(1.8%)

0.670

 Cardiac death, n (%)

7(1.0%)

17(0.8%)

0.617

 

8(1.3%)

0.607

All cause death, n (%)

10(1.4%)

28(1.3%)

0.825

 

11(1.6%)

0.816

Major bleeding, n (%)

6(0.8%)

36(1.7%)

0.112

 

21(3.0%)

0.003

  1. Notes: DCB, Drug-coated balloon; sDES, second-generation drug-eluting stent; MACE, major adverse cardiac events; CD-TLR, clinically driven target lesion revascularization; MI, myocardial infarction; continuous variables were presented as mean ± standard deviation or median (interquartile range, IQR); categoric variables were shown as number (%)